Altimmune Inc.

9:45 AM - 10:00 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Altimmune is a publicly traded (Nasdaq: ALT) clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX and NasoShield).

The Company recently announced an acquisition of Spitfire Pharma Inc. and their NASH product candidate, a fully funded Phase 1b NasoShield trial (BARDA), and the results of a pre-IND meeting on HepTcell.

Altimmune has a strong balance sheet with $42 million in cash at June 30, 2019 and is poised for growth in the near term.
Ticker:
ALT
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
1997
Main Therapeutic Focus:
Lead Product in Development:
ALT-801 for treatment of NASH
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4